Patienter, der udviklede exenatid- antistoffer, havde lignende hyppigheder og typer af bivirkninger, som de der ikke havde udviklet exenatid- antistoffer.
Patients who developed anti-exenatide antibodies had similar rates and types of adverse events as those with no anti-exenatide antibodies.